CEBPD REGULATES OXIDATIVE STRESS AND INFLAMMATORY RESPONSES IN HYPERTENSIVE CARDIAC REMODELING

Jinghong Zhao1, Jilin Hu, Rongyi Zhang

  • 1Department of Cardiology, Nanchong Central Hospital, Nanchong, China.

Shock (Augusta, Ga.)
|September 26, 2023
PubMed

Insights

CCAAT/enhancer-binding protein delta (CEBPD) upregulation mitigates hypertensive cardiac remodeling by reducing oxidative stress and inflammation. CEBPD promotes miR-96-5p, which inhibits inositol 1,4,5-trisphosphate receptor 1 (IP3R) to protect the heart.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Cellular Physiology

Background:

  • Hypertension is a major cause of cardiac remodeling and mortality.
  • The molecular mechanisms underlying hypertensive cardiac remodeling, particularly oxidative stress and inflammation, require further elucidation.

Purpose of the Study:

  • To investigate the role of CCAAT/enhancer-binding protein delta (CEBPD) in hypertensive cardiac remodeling.
  • To explore the molecular pathway involving CEBPD, miR-96-5p, and inositol 1,4,5-trisphosphate receptor 1 (IP3R) in regulating oxidative stress and inflammation.

Main Methods:

  • Established a murine model of hypertension using angiotensin-II injection.
  • Utilized in vivo and in vitro models with CEBPD overexpression to assess cardiac function, histological changes, cell viability, oxidative stress markers, and inflammatory factors.
  • Validated molecular interactions using promoter enrichment, luciferase assays, and gene silencing/overexpression experiments.

Main Results:

  • CEBPD levels were decreased in hypertensive cardiac tissue.
  • Upregulation of CEBPD improved cardiac function, attenuated cardiac fibrosis and hypertrophy, and reduced oxidative stress and inflammation markers (ROS, LDH, MDA, TNF-α, IL-1β, IL-6).
  • CEBPD promoted miR-96-5p expression, which in turn negatively regulated IP3R. Silencing miR-96-5p or overexpressing IP3R reversed the protective effects of CEBPD.

Conclusions:

  • CEBPD plays a protective role in hypertensive cardiac remodeling.
  • The CEBPD/miR-96-5p/IP3R axis inhibits oxidative stress and inflammation, thereby alleviating cardiac remodeling.
  • Targeting the CEBPD pathway may offer a therapeutic strategy for hypertension-induced heart disease.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
110
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
46